

Biochemical and immunological roles of heat shock proteins in human cancer

Christopher Shipp

B. Sc. (Hons)

University of New England

Australia

A thesis submitted for the degree of

Doctor of Philosophy

from the University of New England

School of Science and Technology

University of New England

Armidale, New South Wales, 2351

Australia

November 2011

DECLARATION

I certify that the substance of this thesis has not already been submitted for any degree and is not currently being submitted for any other degree or qualification.

I certify that to the best of my knowledge any help received in the preparation of this thesis, and all sources used, have been acknowledged accordingly.

Christopher Shipp

“To those human beings who are of any concern to me I wish suffering, desolation, sickness, ill-treatment, indignities - I wish that they should not remain unfamiliar with profound self-contempt, the torture of self-mistrust, the wretchedness of the vanquished”

Friedrich Nietzsche

Although probably not an accurate description of the process of obtaining most PhDs, the failures, difficulties and low periods are an important part of the journey and should be savoured and learnt from as much as the successes.

Table of Contents

List of Figures.....	vi
List of Tables.....	viii
Acknowledgements.....	ix
Abstract.....	x
Publications arising from this thesis.....	xii
Aspects of this thesis presented at conference proceedings.....	xiii
Scholarships and financial support.....	xiv
Abbreviations.....	xv
Chapter 1: Introduction.....	1
1.1 Heat Shock Proteins.....	1
1.2 Breast Cancer.....	4
1.3 Melanoma.....	6
1.4 Hsp40.....	7
1.5 Hsp60.....	7
1.6 Hsp70.....	8
1.7 Hsp90.....	9
1.7.1 Hsp90 structure and function.....	10
1.7.2 Hsp90 chaperone activity.....	12
1.8 Geldanamycin.....	18
1.9 Regulation of heat shock protein expression.....	19
1.10 Hsps' role in the immune system.....	20
1.11 Hsps and cancer.....	21
1.12 Hsps and breast cancer.....	24
1.13 Hsps and melanoma.....	25
1.14 The role of hsps in cancer immunity and therapy.....	26
1.15 Thesis Aims.....	30
Chapter 2: Materials and Methods.....	31
2.1 Materials.....	31
2.1.1 Chemicals and consumables.....	31
2.1.2 Antibodies.....	33
2.1.2.1 Primary antibodies.....	33
2.1.2.2 Secondary antibodies.....	33
2.1.3 Plastic ware and general materials.....	33
2.1.4 Peptides.....	34
2.1.5 T cell clones.....	34
2.1.6 Tissue samples and cell lines.....	34
2.1.7 Software and internet resources.....	35
2.1.8 Equipment.....	35
2.2 Methods.....	35
2.2.1 Ethics.....	35
2.2.2 Extraction and isolation of cellular proteins from breast tissue.....	35
2.2.3 Protein quantification of breast tissue extracts.....	36
2.2.4 Immunoprecipitation.....	36
2.2.5 SDS-PAGE separation of protein extracts from breast tissue.....	37
2.2.6 Western immunoblotting of breast tissue.....	37
2.2.7 Staining of acrylamide gels.....	38
2.2.8 Mass spectrometry.....	38

2.2.9 2 Dimensional SDS-PAGE	38
2.2.10 ELISA	39
2.2.11 Immunofluorescence.....	40
2.2.12 Extraction and isolation of cellular proteins from melanoma tissue	41
2.2.13 Melanoma tissue protein extract quantification	41
2.2.14 Western immunoblotting of melanoma tissue.....	42
2.2.15 Stripping of Western blot membranes to allow for multiple probing.....	43
2.2.16 Melanoma cell line culture.....	43
2.2.17 Determination of cell number and viability	43
2.2.18 Flow cytometry.....	44
2.2.19 T cell culture and sensitisation	44
2.2.20 Statistical analysis.....	46
Chapter 3: Heat shock protein expression in tumour and healthy breast tissue	47
3.1 Introduction.....	47
3.2 Results	47
3.3 Discussion.....	52
Chapter 4: Characterisation of heat shock protein 90 client proteins in tumour and healthy breast tissue.....	54
4.1 Introduction.....	54
4.2 Results	55
4.3 Discussion.....	61
Chapter 5: Identification of differential protein expression in primary-derived versus metastasis-derived melanoma cell lines and the effect of stromal cell interactions	67
5.1 Introduction.....	67
5.2 Results	69
5.3 Discussion.....	77
Chapter 6: Heat shock protein expression in melanoma cell lines: effect of culture under low oxygen tension, relationship with cell line characteristics and patient clinical parameters	81
6.1 Introduction.....	81
6.2 Results	83
6.3 Discussion.....	102
Chapter 7: Heat shock protein expression in melanoma tumour tissue and relationship with patient clinical parameters	110
7.1 Introduction.....	110
7.2 Results	111
7.3 Discussion.....	122
Chapter 8: The role of hsp90 in T cell recognition of tumour cells.....	128
8.1 Introduction.....	128
8.2 Results	128
8.3 Discussion.....	133
Chapter 9: Conclusions and Future Directions	136
References	143
Appendix I.....	157
Appendix II.....	186
Appendix III	196
Appendix IV	197
Appendix V	197
Appendix VI.....	204

List of Figures

Figure 1.1 Functions of hsps in maintaining protein homeostasis	3
Figure 1.2 Worldwide breast cancer incidence and mortality	5
Figure 1.3 Melanoma incidence worldwide	6
Figure 1.4 Hsp90 dimerisation model.....	11
Figure 1.5 Role of heat shock proteins in chaperoning the nascent oestrogen receptor	16
Figure 1.6 Proposed model for the role of heat shock proteins in protein degradation	17
Figure 1.7 The role of heat shock proteins in antigen presentation.....	29
Figure 3.1 Hsp70 expression in tumour and healthy breast tissue	48
Figure 3.2 Hsp90 expression in tumour and healthy breast tissue	49
Figure 3.3 2D SDS-PAGE separation of proteins breast tumour and healthy tissue from the same individual	51
Figure 4.1 Geldanamycin-sensitive hsp90 client proteins in tumour and normal breast tissue extracts.....	56
Figure 4.2 Hsp56 Western immunoblot of immunoprecipitated hsp90 client proteins in breast tumour tissue extracts	58
Figure 4.3 Hsp90 client proteins analysed with LC-MS.....	59
Figure 4.4 Geldanamycin resistant hsp90 in breast tumour tissue extracts	60
Figure 5.1 CD44, CD54, CD95, CD155 and MHC I protein expression on primary- and metastasis-derived melanoma cell lines with or without fibroblast co-culture.....	70
Figure 5.2. Heat shock protein expression on primary- and metastasis-derived melanoma cell lines with or without fibroblast co-culture.....	72
Figure 5.3 CD44, CD54, CD95, CD155 and MHC I protein expression on fibroblasts cultured with primary- and metastasis-derived melanoma cell lines.....	74
Figure 5.4 Heat shock protein expression on fibroblasts cultured with primary- and metastasis-derived melanoma cell lines	76
Figure 6.1 Effect of low oxygen tension on melanoma cell line generation time	84
Figure 6.2 Effect of low oxygen tension on heat shock protein expression	86
Figure 6.3 Relationship between heat shock protein expression and melanoma cell line generation time in 2 % or 20 % O ₂ culture conditions.....	88
Figure 6.4 Effect of low oxygen tension on melanoma cell line viability	90
Figure 6.5 Relationship between heat shock protein expression and melanoma cell line viability in 2 % or 20 % O ₂ culture conditions.....	91

Figure 6.6 Heat shock protein expression across melanoma cell lines	93
Figure 6.7 Relationship between the expression of different heat shock proteins in melanoma cell lines cultured under 20 % O ₂	94
Figure 6.8 Relationship between the expression level of different heat shock proteins in melanoma cell lines cultured under 2 % O ₂	95
Figure 6.9 Expression of cell surface heat shock proteins in melanoma cell lines	96
Figure 6.10 Relationship between heat shock protein expression and patient survival in melanoma cell lines.....	97
Figure 6.11 Relationship between heat shock protein expression and Breslow depth in melanoma cell lines.....	98
Figure 6.12 Relationship between heat shock protein expression, ligand adhesion and expression of cell surface proteins in melanoma cell lines.....	99
Figure 6.13 Effect of geldanamycin and methylene blue on melanoma cell line growth.....	102
Figure 7.1 Heat shock protein expression in melanoma, a squamous cell carcinoma and a lymph node from a patient with B cell chronic lymphocytic leukaemia	113
Figure 7.2 Heat shock protein expression level in melanoma tumour tissue	118
Figure 7.3 Fluorescence microscopy of heat shock protein expression in melanoma and non-melanoma cells within melanoma tumour tissue	119
Figure 7.4 Fluorescence microscopy of heat shock protein expression in melanoma tumour tissue	120
Figure 8.1 Effect of hsp90 inhibition on T cell line recognition of melanoma cells	129
Figure 8.2 Effect of pre-treating melanoma cells with geldanamycin on T cell and melanoma cell viability in co-culture experiments	130
Figure 8.3 Effect of geldanamycin on melanoma cell line MHC expression	131
Figure 8.4 Effect of hsp90 inhibition on recognition of melanoma cells by a MelanA-specific CD8 ⁺ T cell clone	132

List of Tables

Table 3.1 Relationship between oestrogen receptor, progesterone receptor and HER2 expression in breast tumour tissue	50
Table 6.1 Change in hsp expression in response to low oxygen tension	87
Table 6.2 Changes in expression of surface marker proteins in response to hsp90 inhibition	101
Table 7.1 Association between hsp90 expression and patient clinical parameters	116

Acknowledgements

Like all PhD journeys, a number of people have assisted me in their own way throughout my candidature. I was fortunate to spend a considerable period of time in two laboratories, and for this reason acknowledgements are made chronologically.

To my principal supervisor Associate Professor Graham Lloyd Jones whose willingness and foresight convinced me not only that splitting my PhD across two universities would be possible, but that it would also be in my self interest. From the time of starting my honours Graham has helped cultivate my development as a scientist. Co-supervisor Professor Ken Watson who provided insight, expertise and experience at crucial times during this project and for his meticulous assistance in the revision of this thesis. One thing I appreciated the most was the freedom given to me by these supervisors that allowed me to pursue this project in my own way.

Dr Linda Agnew who was of great help with certain technical aspects of this project. Dr Joëlle Coumans-Moens for teaching me the fine art of 2D SDS-PAGE. Other academic staff members in the McClymont building as well as the technical and admin staff (Melody Parkes, Annette McLeod) who each provided assistance in their own way.

Dr Roger Lord (Australian Catholic University, Brisbane), Dr Guy Hingston (Port Macquarie Private Hospital) and Dr Frank Sardelic (Tamworth base hospital) and associated staff and patients who made valuable contributions in the collection of breast tissue samples.

The second phase of this PhD would not have been possible if it were not for Professor Graham Pawelec. After a brief visit in Tübingen he agreed to host me in his lab, and when confirming this with a handshake he commented that he thought that in Australian culture this was akin to a binding legal agreement. Despite a busy schedule, Graham was there to provide input and critical analysis when needed.

Dr Evelyn Derhovanessian who provided regular guidance with the project, yet allowed enough freedom in order for me to explore my own ideas. Her supervision has added significantly to my development as a scientist.

To the rest of the TATI group: Henning Zelba, Lilly Öttinger, Karin Hähnel, David Goldeck, Valeria Pellicano, former members and the Zivis (Simon Walker, Markus Claus) who have all contributed to different parts of this project. The other groups in the ZMF (AG Klein, GK Aicher and the anaesthesiology group), particularly Paulina Rymkiewicz who helped with technical aspects of immunofluorescence experiments.

Dr med. Benjamin Weide (University of Tübingen Dermatology Clinic) for clinical expertise and for providing all of the melanoma tissue samples, as well as staff at the Tübingen dermatology clinic for immunofluorescence help. Dr Simon Völkl (University of Erlangen-Nürnberg) for providing T cell clones and the expertise required for their culture. Dr Martin Deeg (Centre for Medical Research, University of Tübingen, Germany) and Dr Gerold Schwarz (Panatecs, Tübingen, Germany) for LC-MS assistance.

Finally, I would like to thank Elyse Beck and my friends and family for providing personal support throughout this time.

I would also like to acknowledge my appreciation for financial support provided by the Australian government and the University of New England.

Abstract

Found in every cell of every organism, heat shock proteins (hsps) participate in a wide range of cellular processes and primarily function as molecular chaperones that mediate the activity of other cellular proteins. Hsps are required for a range of fundamental mechanisms used by cancer cells and they have consequently been identified as valid targets in the treatment of cancer. It was the aim of this thesis to further investigate these roles in breast cancer and melanoma using novel approaches from a biochemical and immunological perspective.

In a preliminary study, breast cancer tissues ($n = 30$) were demonstrated by Western immunoblotting to widely express hsps 90 and 70. Two-dimensional gel electrophoresis indicated that a number of proteins were differentially expressed in tumour and healthy breast tissue from the same patient. These results suggest that a number of possibly unidentified proteins may play important roles in breast cancer and thus have use as therapeutic targets or biomarkers. The role of hsp90 and associated client proteins in breast cancer was further investigated by non-denaturing immunoprecipitation followed by elution with geldanamycin, a specific inhibitor of hsp90. Geldanamycin-sensitive hsp90 client proteins were observed in seven of 11 protein extracts from breast cancer patients and one healthy individual. Immunoprecipitation, Western immunoblotting and LC-MS identified hsps 40, 56/FKBP52, 60, 70, 105 and lumican as potential hsp90 client proteins. These proteins may thus assist breast cancer progression alongside hsp90. In one patient sample, a cancer-specific group of proteins was identified, while in all experiments geldanamycin resistance was observed. The results of this study may have relevance for the future of breast cancer research and clinical treatment.

Cell surface proteins involved in cell adhesion, apoptosis, antigen presentation as well as hsps were investigated for their role in melanoma metastasis. In addition, the influence of co-culture with stromal cells was investigated as a potential model system for *in vivo* growth conditions. Matched sets of primary-derived versus metastasis-derived melanoma cell lines were cultured and screened for the expression of CD44, CD54, CD95, CD155, MHC I, hsps 90, 70, 60, 40 and 32. In some instances, differential protein expression was observed in metastasis-derived cell lines as compared to lines derived from primary tumours, and although a number of consistent changes in protein expression were observed within the cell lines, these were not exclusively associated with primary or metastatic tumour origin.

Hypoxia is a well established characteristic of cancer cells. Paradoxically, *in vitro* studies on cancer cell lines are routinely performed under hyperoxic conditions. In this study, melanoma cell lines were cultured under high (20 % O₂, $n = 42$) and low (2 % O₂, $n = 18$) oxygen tension and monitored for the expression of hsps 90, 70, 60, 40 and 32. Total higher expression of hsps 90, 70 and 60 correlated with improved viability in low ($P < 0.05$) but not high oxygen tension. Relative hsp expression was consistent across the cohort of cell lines and the expression levels of hsps 90, 70, 60 and 40 correlated with one another ($P = 0.0001$), but not with hsp32. Expression of hsp90 was associated with cell line adhesion to collagen type IV and laminin ($P < 0.05$). Expression of hsp90 and hsp40 correlated with Breslow depth of the primary tumour from which these metastatic tumour cell lines were derived ($P < 0.04$), however, hsp expression was not correlated with other clinical parameters including Clark level or patient survival. Interestingly, all hsps were identified on the cell surface and these proteins may thus play roles in tissue invasion, metastasis and immunological recognition.

Using Western immunoblotting to examine the expression of hsp90, hsp70, hsp60, hsp40 and hsp32 in uncultured metastatic melanomas (n = 32) demonstrated that these proteins are widely expressed in melanoma tumour tissue. Correlating the expression of these hsps with patient clinical parameters showed that increased hsp90 ($P < 0.02$) and hsp40 ($P < 0.03$) expression was correlated with progression to advanced tumour stage (stage III to stage IV), higher hsp90 expression correlated with reduced patient follow-up time ($P < 0.04$) (survival since removal of the metastatic tumour that was therein examined) and hsp70 expression was associated with sex of the patient ($P < 0.05$). On the other hand, expression of the other hsps was not associated with any recorded patient clinical parameters. Fluorescence microscopy of whole melanoma tissues using the MelanA antigen as a specific marker for melanoma cells demonstrated increased expression of hsps 90, 70, 60, 40 and 32 in MelanA-positive cells compared to adjacent MelanA-negative (non-melanoma) cells. These data contribute to the proposal that hsps are valid therapeutic targets in the treatment of melanoma.

The role of hsp90 in the immunological recognition of cancer cells was investigated by treating target melanoma cells with the hsp90 inhibitor geldanamycin and using T cell lines and T cell clones as effector cells. Geldanamycin treatment was observed to abrogate the recognition of melanoma cells by T cell lines. In contrast, under identical conditions, T cell clones were able to recognise geldanamycin-treated melanoma cells. These data allude to the complexity of the hsp90 molecular chaperone and may have consequences for the rarely considered immunological aspects of hsp90 inhibitors used clinically.

The present studies employed a diverse range of experimental approaches to examine the role of hsps, hsp-client proteins and cell surface proteins in a wide range of human cancer cells, including breast cancer, melanomas and related cell lines. A number of novel experimental approaches were developed which included screening of hsp expression in matched primary and metastatic tumour cell lines, the adoption of cancer cell line culture under conditions of low oxygen tension, immunofluorescence to identify hsp expression in melanoma and adjacent non-melanoma cells *in situ* and attempts to relate hsp expression to patient clinical parameters. The overall outcomes of these studies have clearly demonstrated a critical role for hsps in cancer pathogenesis and in the immune recognition of cancer cells. Moreover, these studies have provided fresh evidence that hsps provide a valid therapeutic target in the treatment of cancers. Nevertheless, many of the present results were equivocal and contradicted some previous studies. These observations simply confirm our limited understanding of the complexities of cancer pathogenesis and the hsp molecular chaperone system.

Publications arising from this thesis

Shipp, C., Watson, K., Jones, G.L. Associations of HSP90 Client Proteins in Human Breast Cancer. *Anticancer Research* 2011; 31(6): 2095-2101.

Shipp, C., Derhovanessian, E. and Pawelec, G. Effect of culture at low oxygen tension on the expression of heat shock proteins in a panel of melanoma cell lines. (Accepted by PLoS ONE)

Shipp, C., Weide, B., Derhovanessian, E. and Pawelec, G. Hsps are up-regulated in melanoma tissue and correlate with patient clinical parameters. (In preparation)

Copies of these manuscripts appear in Appendix I

Aspects of this thesis presented at conference proceedings

Shipp, C., Watson, K., and Jones G. L. Stress Proteins in Human Breast Cancer. P27. EMBO meeting on Cellular Signalling and Molecular Medicine. pp 114 – 115. Cavtat, Croatia. May 29th – June 4th (2008) (Poster)

Shipp, C., Watson, K., and Jones G. L. Stress protein interactions in human breast cancer. University of New England Faculty of Arts and Sciences Postgraduate Research Conference. University of New England, Armidale, Australia. Nov 14th – 15th (2008) (Lecture)

Shipp, C., Watson, K., and Jones, G. L. Hsps 70 and 105 associate with a group of hsp90 client proteins that are selectively found in human breast cancer. D5. International Symposium on Signal Transduction and Disease. pp 87-88. Aachen, Germany. September 27th – 30th (2009). (Poster)

Shipp, C., Watson, K., Jones, G. L. Hsp90 client proteins in human breast cancer. The 5th International Conference on The Hsp90 Chaperone Machine. pp 126. Les Diablerets, Switzerland. Sep 29th – Oct 3rd (2010) (Poster)

Shipp, C., Derhovanessian, E. and Pawelec, G. Biochemical and immunological roles of hsps in human melanoma. P87. EMBO meeting on The Biology of Molecular Chaperones. pp 152. Grudlsee, Austria. May 19th – 24th (2011) (Poster)

Copies of abstracts and posters appear in Appendix II

Scholarships and financial support

Australian Postgraduate Award (2008-2011)

University of New England Strategic Doctoral Scholarship (2008-2011)

Run For Your Life Postgraduate Research Award (2009)

Keith and Dorothy Mackay Travelling Scholarship (2009)

University of New England School of Science and Technology Conference Grant (2010)

Abbreviations

17-AAG	17-Allylamino-17-demethoxygeldanamycin
2D SDS-PAGE	2 Dimensional Sodium Dodecyl Sulphate-PolyAcrylamide Gel Electrophoresis
ABTS	2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)
APC	Antigen Presenting Cell
ASI	Age Standardised Index
ADP	Adenosine Diphosphate
ATP	Adenosine Triphosphate
CD	Cluster of Differentiation
CHAPS	3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate
CHIP	C-terminus of Hsp70-Interacting Protein
DC	Dendritic Cell
ddH ₂ O	Distilled De-ionised Water
DTT	Dithiothreitol
ECL	Enhanced Chemiluminescence
EDTA	Ethylenediaminetetraacetic acid
EHS	Engelbreth-Holm-Swarm
ELISA	Enzyme-Linked Immunosorbent Assay
ER	Endoplasmic Reticulum
EST	European Searchable Tumour Line
ESTDAB	European Searchable Tumour Line Database
FACS	Fluorescence Activated Cell Sorting
FCS	Foetal Calf Serum
FI	Fluorescence Index
FITC	Fluorescein Isothiocyanate
FKBP52	FK506-Binding Protein 52
GM-CSF	Granulocyte-Macrophage Colony-Stimulating Factor
HER2	Human Epidermal Growth Factor Receptor 2
HIF1 α	Hypoxia-Inducible Factor 1 alpha
HLA	Human Leukocyte Antigen
HRP	Horseradish Peroxidase

HSE	Heat Shock Element
HSF	Heat Shock Factor
hsp	Heat Shock Protein
IFN	Interferon
IL	Interleukin
kDa	Kilodalton
LPS	Lipopolysaccharide
LC-MS	Liquid Chromatography-Mass Spectrometry
MHC	Major Histocompatibility Complex
MMP	Matrix Metalloproteinase
mRNA	Messenger Ribonucleic Acid
NK	Natural Killer (cell)
OR	Oestrogen Receptor
PBMC	Peripheral Blood Mononuclear Cell
PBS-T	Phosphate Buffered Saline-Tween 20
PE	Phycoerythrin
pI	Isoelectric Point
PMSF	Phenylmethanesulfonyl Fluoride
PO	Pacific Orange
PPI	Peptidyl-prolyl Isomerase
PR	Progesterone Receptor
SDS	Sodium Dodecyl Sulphate
SMP	Skim Milk Powder
TAP	Transporter Associated with Antigen Processing
TPR	Tetratricopeptide Repeat
Tris	Tris(hydroxymethyl)aminomethane
Tween 20	Polyoxyethylenesorbitan monolaurate
TEMED	N,N,N',N'-Tetramethylethylenediamine